The efficacy and role of Secukinumab

Studies have shown that Secukinumab is effective in treating psoriasis, psoriatic arthritis and spinal arthritis. In four psoriasis studies involving2,403 adults, 79% of patients taking secukinumab experienced a 75% decrease in their PASI score (a measure of disease severity and area of u200bu200baffected skin) after 12 weeks of treatment, and 65% of patients taking secukinumab had clear or nearly clear skin. In a study of 162 children over 6 years old with severe psoriasis, approximately 80% of children treated with secukinumab experienced a 75% reduction in PASI scores, and approximately 70% of children had significant or little psoriasis-free skin after 12 weeks.

In a study of 397 patients with psoriatic arthritis, 51% to 54% of patients who received the approved dose of secukinumab experienced a 20% reduction in their ACR score (pain, joint swelling and other symptoms) after 24 weeks. In a study of 219 adults with ankylosing spondylitis, 61% experienced a 20% decrease in ASAS scores (back pain, morning stiffness and other symptoms) after 16 weeks of treatment with secukinumab at an approved dose. In another study involving 555 adults with non-radiographic axial spondyloarthritis, 41% of patients who received the approved dose of secukinumab experienced a 40% reduction in ASAS score after 16 weeks.

In a study involving 75 children aged 2 to 17 years with active ERA or JPsA, fewer patients who took secukinumab had their disease worsen (10 vs. 21). Because the study included only a few children younger than 6 years of age, the data for this age group are uncertain, so secukinumab was started at 6 years of age. In 2 studies involving 1,084 adults with moderate to severe hidradenitis suppurativa, 44% of patients treated with secukinumab experienced at least a 50% reduction in abscesses and nodules after 16 weeks, without any increase in the number of abscesses or fistulas (abnormal passages). However, secukinumab increases the risk of infection, so it must not be used for patients with severe infections such as tuberculosis.

Secukinumab The original drug has been launched in China and has entered the scope of Class B medical insurance. However, domestic patients who can purchase this drug are limited to eligible patients with psoriasis and ankylosing spondylitis. Patients who are not eligible for medical insurance reimbursement can only purchase it at their own expense. The price of each box of 150mg/ML is about RMB 1,000. SecukinumabThe original drug has also been launched overseas, and the specifications of the original version in TürkiyeThe price per box of 150mg/ML is around RMB 1,500. The price per box of the European version of 150mg/ML*2 tubes is around RMB 15,000 (the price may fluctuate due to the exchange rate). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic version of secukinumab produced and launched.